International Triadin Knockout Syndrome Registry
- 1 February 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 12 (2) , e002419
Abstract
Background: Triadin knockout syndrome (TKOS) is a rare, inherited arrhythmia syndrome caused by recessive null mutations in TRDN -encoded cardiac triadin. Based previously on 5 triadin null patients, TKOS has been characterized by extensive T-wave inversions, transient QT prolongation, and severe disease expression of exercise-induced cardiac arrest in early childhood refractory to conventional therapy. Methods: We have established the International Triadin Knockout Syndrome Registry to include patients who have genetically proven homozygous/compound heterozygous TRDN null mutations. Clinical/genetic data were collected using an online survey generated through REDCap. Results: Currently, the International Triadin Knockout Syndrome Registry includes 21 patients (11 males, average age of 18 years) from 16 families. Twenty patients (95%) presented with either cardiac arrest (15, 71%) or syncope (5, 24%) at an average age of 3 years. Mild skeletal myopathy/proximal muscle weakness was noted in 6 (29%) patients. Of the 19 surviving patients, 16 (84%) exhibit T-wave inversions, and 10 (53%) have transient QT prolongation > 480 ms. Eight of 9 patients had ventricular ectopy on exercise stress testing. Thirteen (68%) patients have received implantable defibrillators. Despite various treatment strategies, 14 (74%) patients have had recurrent breakthrough cardiac events. Conclusion: TKOS is a potentially lethal disease characterized by T-wave inversions in the precordial leads, transient QT prolongation in some, and recurrent ventricular arrhythmias at a young age despite aggressive treatment. Patients displaying this phenotype should undergo TRDN genetic testing as TKOS may be a cause for otherwise unexplained cardiac arrest in young children. As gene therapy advances, enrollment into the International Triadin Knockout Syndrome Registry is encouraged to better understand TKOS and to ready a well-characterized cohort for future TRDN gene therapy trials.Keywords
This publication has 40 references indexed in Scilit:
- Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in humanHuman Molecular Genetics, 2012
- Short Communication: Flecainide Exerts an Antiarrhythmic Effect in a Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia by Increasing the Threshold for Triggered ActivityCirculation Research, 2011
- Flecainide Therapy Reduces Exercise-Induced Ventricular Arrhythmias in Patients With Catecholaminergic Polymorphic Ventricular TachycardiaJACC, 2011
- Systematic Review of the Incidence of Sudden Cardiac Death in the United StatesJACC, 2011
- Triadin Deletion Induces Impaired Skeletal Muscle FunctionJournal of Biological Chemistry, 2009
- New roles of calsequestrin and triadin in cardiac muscleThe Journal of Physiology, 2009
- Ablation of triadin causes loss of cardiac Ca 2+ release units, impaired excitation–contraction coupling, and cardiac arrhythmiasProceedings of the National Academy of Sciences, 2009
- The normal ECG in childhood and adolescenceHeart, 2005
- Influence of the Genotype on the Clinical Course of the Long-QT SyndromeNew England Journal of Medicine, 1998
- Structural diversity of triadin in skeletal muscle and evidence of its existence in heartFEBS Letters, 1994